- Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more about Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022

Read more about Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022

Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index

Read more about Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index

Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

Read more about Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference

Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease

Read more about Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease

Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray

Read more about Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray

Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021

Read more about Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021

Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Read more about Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of Dry Eye Disease

Read more about Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of Dry Eye Disease

Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye Disease

Read more about Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye Disease

Print Page button

Email Alerts button

Information Request button

Information Request

© 2022 Oyster Point Pharma, Inc., TYRVAYA™, and the Oyster Point logo are trademarks of Oyster Point Pharma, Inc.